Manuscript Section		Item No	Item Description	Is the item addressed in the manuscript	If Yes, the page Number (Pg) The paragraph number (Ph)	How satisfactory is? n %	Other comments
Title and abstract and keywords							
Title		A1	Be concise, clear, and comprehensive. Indicate the main variables, including the name of the natural product (generic or scientific), the histopathologic type of cancer, *in vitro* model system, and assessed outcome. Abbreviations should be avoided.	Yes / No	Pg / Ph		
A Structured Abstract	Objective	A2-1	Present an objective that includes the name of natural product, the histopathologic type of cancer as the disease of interest, *in vitro* model system, and outcome measure	Yes / No	Pg / Ph		
	Methods	A2-2	Briefly describe the natural product preparation, *in vitro* model, and anticancer assay method	Yes / No	Pg / Ph		
	Result	A2-3	Report all meaningful anticancer effects.	Pg / Ph	Pg / Ph		
	Conclusion	A2-4	Give a qualitative assessment of the anticancer effect of the natural compound	Pg / Ph	Pg / Ph		
Introduction							
Background /rationale		I1	Introduce the natural product and state its ingredients	Yes / No	Pg / Ph		
		I2	Justify the rationale of the selection of the test agent as a probable candidate for cancer prevention or treatment	Yes / No	Pg / Ph		
Objectives		I3	Outline the purpose and state the specific objectives of the research, indicating the novelty of the work	Yes / No	Pg / Ph		
Material and Methods							
Natural product characteristics		M1	Indicate the geographical location and time of specimen collection	Yes / No	Pg / Ph		
		M2	Indicate which parts of the natural entity were used for bioassay (e.g., leaves, twigs, bark, flowers, fruits, roots, etc.)	Yes / No	Pg / Ph		
		M3	Describe the extraction method (e.g., Soxhlet, microwave-assisted extraction, ultrasound-based extraction, etc.), indicating the name of solvents	Yes / No	Pg / Ph		
		M4	In the case of plant extracts, indicate the method of	Yes	Pg		

		dealing with the precipitation of the test preparation in the assay medium	No	Ph		
	M5	Indicate the physicochemical characterization of the test product and state what methods were used for the characterization	Yes No	Pg Ph		
Materials and reagents	M6	Indicate the name of all reagents and chemicals with all vendor details, including company/institution and country	Yes No	Pg Ph		
	M7	If commercial antibodies are used, report the code number in addition to the information mentioned above. For academic antibodies, report the source laboratory and relevant references.	Yes No	Pg Ph		
In vitro model system characteristics	M8	Indicate the category of *in vitro* model system (cell line, tumoroid, tissue model, etc.), including host origin (human, mouse, etc.) and the relevant histopathologic type of cancer	Yes No	Pg Ph		
	M9	Describe the culture conditions of *in vitro* model (media, growth factors, incubation characteristics, etc.)	Yes No	Pg Ph		
	M10	Indicate the authentication of *in vitro* model system and state what method was used for authentication	Yes No	Pg Ph		
	M11	Confirm that mycoplasma testing has been done for *in vitro* model system	Yes No	Pg Ph		
Experimental outcomes	M12	Clearly define the primary and secondary experimental outcomes assessed (e.g., survival fraction, growth inhibition, cell migration, angiogenesis, etc.)	Yes No	Pg Ph		
Design of experiment	M13	Specify the number of replications (n) per each intervention. Explain how the number of replications decided. Provide details of any sample size calculation used.	Yes No	Pg Ph		
	M14	Indicate the use of multiple biological entities (numerous cell lines, organoids, etc.) from biologically independent sources as experimental units	Yes No	Pg Ph		
	M15	Indicate the random assignment of experimental units to the various groups. Report the method of randomization.	Yes No	Pg Ph		
	M16	Report the allocation concealment, blinded conduct of the experiment, and blinded assessment of outcomes.	Yes No	Pg Ph		
	M17	Indicate the assessment method of outcomes	Yes	Pg		

			No	Ph		
	M18	Report the concentrations of the test product and exposure times	Yes No	Pg Ph		
	M19	If variables such as IC_{50} (GI_{50}) or EC_{50} are outcomes of interest, indicate the use of the four-parametric logistic model. Indicate the use of at least five concentrations of the test product to calculate the variables mentioned above.	Yes No	Pg Ph		
	M20	Indicate the use of appropriate positive and negative controls	Yes No	Pg Ph		
	M21	Indicate the use of normal biological entities (normal cell lines, normal organoids, etc.) beside neoplastic models if selective cytotoxicity has been assessed	Yes No	Pg Ph		
	M22	Express the use of the appropriate method of drug interaction analysis if synergism/antagonism has been assessed	Yes No	Pg Ph		
Statistical analysis	M23	Provide details of the statistical methods used for each analysis	Yes No	Pg Ph		
	M24	Specify the unit of analysis for each dataset	Yes No	Pg Ph		
	M25	Report any methods used to assess whether the data met the assumptions of the statistical approach.	Yes No	Pg Ph		
	M26	Name the statistical software used.	Yes No	Pg Ph		
Ethics code	M27	Report protocol approval by the ethics committee.	Yes No	Pg Ph		
Results						
Baseline data	R1	For each experimental group, report relevant characteristics of the *in vitro* model before treatment	Yes No	Pg Ph		
Numbers analyzed	R2	Report the number of experimental units in each group included in each analysis. Report absolute numbers (e.g., 2/4, not 50%)	Yes No	Pg Ph		
	R3	If any data has not been included in the analysis, explain why. Attrition information for each group should be reported.	Yes No	Pg Ph		
Outcomes and estimation	R4	Report the results for each analysis carried out, with	Yes	Pg		

		a measure of precision (e.g., standard error or confidence interval)	No	Ph		
Key results	D1	Summarize key results with reference to study objectives.	Yes No	Pg Ph		
Interpretation/scientific implications	D2	Interpret the results, considering the study objectives and hypothesis, current theory, and other relevant studies in the literature.	Yes No	Pg Ph		
Limitations	D3	Explain the limitations of the study in methodology or findings	Yes No	Pg Ph		
Generalizability/translation	D4	Comment on whether and how this study's findings are likely to translate to other biological systems, including any relevance to human cancers.	Yes No	Pg Ph		
Acknowledgment section						
How and if the study was financed	Ak1	List all funding sources (including grant number) and the funder(s) role in the study.	Yes No	Pg Ph		
Is the experimental protocol registered in any registry system?	Ak2	Report if the experimental protocol has been registered in the journals or online resources	Yes No	Pg Ph		